DH Stock Price, Definitive Healthcare . Quote, Chart

Market Summary

USD6.99+0.26

Market Closed

3.86%

DH Stock Price

View Fullscreen

DH RSI Chart

DH Valuation

Market Cap

822.9M

Price/Earnings (Trailing)

-4

Price/Sales (Trailing)

3.27

EV/EBITDA

-3.68

Price/Free Cashflow

21.53

DH Price/Sales (Trailing)

DH Profitability

EBT Margin

-122.58%

Return on Equity

-17.17%

Return on Assets

-11.27%

Free Cashflow Yield

4.64%

DH Fundamentals

DH Revenue

Revenue (TTM)

251.4M

Rev. Growth (Yr)

8.8%

Rev. Growth (Qtr)

0.93%

DH Earnings

Earnings (TTM)

-205.9M

Earnings Growth (Yr)

-168.51%

Earnings Growth (Qtr)

96.06%

Breaking Down DH Revenue

Last 7 days

-1.0%

Last 30 days

-11.6%

Last 90 days

-23.4%

Trailing 12 Months

-34.9%

How does DH drawdown profile look like?

DH Financial Health

Current Ratio

2.31

Debt/Equity

0.2

Debt/Cashflow

0.17

DH Investor Care

Shares Dilution (1Y)

9.41%

Diluted EPS (TTM)

-1.78

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	231.7M	238.1M	246.1M	251.4M
2022	179.3M	194.1M	208.4M	222.7M
2021	128.9M	140.5M	153.5M	166.2M
2020	0	0	0	118.3M
2019	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Definitive Healthcare Corp.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 14, 2024	krantz jason ronald	sold (taxes)	-22,716	8.09	-2,808	interim ceo
Mar 14, 2024	booth richard douglas	sold (taxes)	-8,033	8.09	-993	chief financial officer
Mar 14, 2024	shamsuddin kate marie	sold (taxes)	-8,445	8.09	-1,044	chief product officer
Feb 16, 2024	krantz jason ronald	sold (taxes)	-54,135	9.99	-5,419	interim ceo
Feb 14, 2024	krantz jason ronald	acquired	-	-	417,752	interim ceo
Feb 14, 2024	booth richard douglas	acquired	-	-	232,911	chief financial officer
Feb 14, 2024	shamsuddin kate marie	acquired	-	-	121,831	chief product officer
Feb 14, 2024	lazorchak carrie	acquired	-	-	35,833	chief revenue officer
Feb 14, 2024	maack jonathan	acquired	-	-	214,995	president
Feb 03, 2024	maack jonathan	sold (taxes)	-92,471	8.61	-10,740	president

Which funds bought or sold DH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	unchanged	-	-30,310	130,807	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-20,000	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	added	13.9	-792,798	9,742,760	-%
Apr 25, 2024	nVerses Capital, LLC	new	-	53,262	53,262	0.13%
Apr 25, 2024	NATIXIS ADVISORS, L.P.	reduced	-27.03	-370,000	538,000	-%
Apr 25, 2024	Valeo Financial Advisors, LLC	added	0.53	-139,373	383,163	0.01%
Apr 25, 2024	Mendota Financial Group, LLC	unchanged	-	-1,215	5,246	-%
Apr 25, 2024	Allworth Financial LP	sold off	-100	-189	-	-%
Apr 24, 2024	RAYMOND JAMES TRUST N.A.	reduced	-23.57	-108,224	176,994	-%
Apr 24, 2024	BROWN ADVISORY INC	added	0.55	-7,186,040	31,945,500	0.04%

Are Funds Buying or Selling DH?

Are funds buying DH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DH

No. of Funds

Unveiling Definitive Healthcare Corp.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	advent international, l.p.	53.7%	62,493,676	SC 13G/A
Feb 13, 2024	krantz jason ronald	15.8%	21,787,263	SC 13G/A
Feb 09, 2024	sea vii management, llc	10.6%	13,811,367	SC 13G/A
Feb 08, 2024	echo street capital management llc	0%	0	SC 13G/A
Jan 05, 2024	conestoga capital advisors, llc	5.01%	5,824,812	SC 13G
Feb 14, 2023	echo street capital management llc	5.5%	5,751,074	SC 13G
Feb 14, 2023	sea vii management, llc	17.4%	22,124,496	SC 13G/A
Feb 13, 2023	krantz jason ronald	16.97%	21,387,853	SC 13G/A
Feb 14, 2022	advent international corp/ma	64.4%	62,493,676	SC 13G
Feb 14, 2022	sea vii management, llc	21.2%	26,747,318	SC 13G

Recent SEC filings of Definitive Healthcare Corp.

View All Filings

Date Filed	Form Type	Document
Apr 09, 2024	ARS	ARS
Apr 09, 2024	DEF 14A	DEF 14A
Apr 09, 2024	DEFA14A	DEFA14A
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Feb 29, 2024	S-8	Employee Benefits Plan
Feb 28, 2024	10-K	Annual Report
Feb 28, 2024	8-K	Current Report
Feb 20, 2024	4	Insider Trading

Peers (Alternatives to Definitive Healthcare Corp.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	456.6B	371.6B	0.44%	0.97%	20.4	1.23	14.64%	11.24%
CI	103.6B	195.3B	-2.45%	41.59%	19.29	0.53	8.17%	-20.79%
CVS	84.5B	357.8B	-15.42%	-8.05%	10.12	0.24	10.95%	93.52%
HCA	81.1B	65.0B	-7.58%	8.53%	15.47	1.25	7.86%	-7.11%
CNC	39.7B	155.5B	-5.58%	8.00%	14.51	0.26	6.34%	84.42%
DVA	11.7B	12.1B	-2.44%	51.70%	16.93	0.96	4.57%	23.40%
UHS	11.5B	14.3B	-8.81%	13.72%	16.01	0.8	6.59%	6.24%
MID-CAP
CHE	8.5B	2.3B	-13.21%	2.71%	31.02	3.73	6.06%	9.17%
ACHC	6.8B	2.9B	-6.00%	1.13%	-313.66	2.32	12.20%	-107.93%
AMN	2.2B	3.8B	-7.09%	-33.84%	10.27	0.57	-27.73%	-52.50%
AMEH	2.0B	1.4B	-10.80%	1.66%	33.48	1.47	21.19%	34.42%
SMALL-CAP
ADUS	1.5B	1.1B	-8.94%	-17.15%	24.52	1.45	11.31%	35.83%
BKD	1.3B	3.0B	5.61%	63.76%	-6.97	0.44	6.74%	20.73%
BEAT	52.7M	-	-9.91%	-0.99%	-3.6	-	-	-12.94%
AMS	20.1M	21.3M	17.84%	15.27%	37.65	0.94	8.00%	-62.25%

Definitive Healthcare Corp. News

Latest updates

Definitive Healthcare Corp. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q2
Revenue	0.9%	66.00	65.00	61.00	59.00	61.00	57.00	55.00	50.00	46.00	43.00	40.00	37.00	34.00	30.00	28.00	26.00	-	-
Gross Profit	0.0%	53.00	53.00	50.00	47.00	51.00	48.00	43.00	39.00	35.00	33.00	30.00	27.00	25.00	23.00	21.00	19.00	-	-
Operating Expenses	-81.8%	63.00	349	62.00	60.00	61.00	58.00	55.00	50.00	49.00	37.00	37.00	30.00	33.00	24.00	23.00	24.00	-	-
S&GA Expenses	3.5%	24.00	23.00	25.00	23.00	24.00	21.00	24.00	21.00	17.00	14.00	13.00	12.00	11.00	8.00	8.00	8.00	-	-
R&D Expenses	7.5%	12.00	11.00	10.00	10.00	10.00	9.00	9.00	7.00	6.00	5.00	4.00	4.00	3.00	3.00	2.00	2.00	-	-
EBITDA Margin	2.6%	-1.01*	-1.04*	0.01*	0.02*	0.03*	0.02*	-0.04*	-0.04*	0.01*	0.05*	0.15*	0.20*	-	-	-	-	-	-
Interest Expenses	0.1%	4.00	4.00	4.00	4.00	1.00	3.00	3.00	2.00	2.00	7.00	8.00	8.00	9.00	9.00	9.00	9.00	-	-
Income Taxes	106.7%	1.00	-17.53	-1.48	-0.71	-17.04	-0.01	-0.21	-0.43	0.00	-0.21	-0.24	-0.24	-	-	-	-	-	-
Earnings Before Taxes	95.4%	-12.19	-266	-13.09	-16.68	-11.16	-6.90	-10.35	-13.46	-14.86	-21.58	-15.37	-10.95	-16.36	-10.26	-11.82	-14.16	-	-
EBT Margin	1.8%	-1.23*	-1.25*	-0.20*	-0.19*	-0.19*	-0.22*	-0.31*	-0.36*	-0.38*	-0.42*	-0.38*	-0.38*	-	-	-	-	-	-
Net Income	96.1%	-6.76	-171	-11.60	-15.97	10.00	-3.02	-10.14	-13.04	-9.86	-7.98	-	-	-	-	-	-	-	-
Net Income Margin	-6.5%	-0.82*	-0.77*	-0.09*	-0.08*	-0.07*	-0.17*	-0.21*	-0.17*	-0.11*	-0.05*	-	-	-	-	-	-	-	-
Free Cashflow	-55.2%	4.00	9.00	11.00	14.00	-9.09	9.00	15.00	13.00	3.00	-1.28	8.00	13.00	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																		(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	0.3%	1,826	1,820	2,105	2,117	2,123	2,121	2,124	2,143	2,118	1,871	1,731	1,739	1,747	1,741	1,734	1,728	1,721	-
Current Assets	4.9%	394	375	421	421	414	402	396	392	444	227	-	-	64.00	-	-	-	36.00	35.00
Cash Equivalents	69.1%	131	77.00	132	125	147	229	228	230	387	190	38.00	33.00	25.00	35.00	-	-	9.00	19.00
Net PPE	-3.4%	4.00	5.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	5.00	-	-	3.00	-	-	-	3.00	-
Goodwill	0.1%	1,075	1,074	1,325	1,325	1,325	1,325	1,325	1,325	1,263	1,263	1,263	1,263	1,263	-	-	-	1,233	19.00
Liabilities	1.7%	627	616	649	653	641	648	640	649	618	591	560	557	554	542	530	517	505	37.00
Current Liabilities	16.0%	171	147	148	151	141	129	126	128	123	107	102	95.00	91.00	85.00	97.00	98.00	70.00	37.00
Long Term Debt	-1.3%	243	246	249	252	256	259	261	262	264	265	-	-	457	-	-	-	435	-
LT Debt, Current	0%	14.00	14.00	12.00	10.00	9.00	7.00	7.00	7.00	7.00	7.00	-	-	5.00	-	-	-	-	-
LT Debt, Non Current	-1.3%	243	246	249	252	256	259	261	262	264	265	-	-	457	-	-	-	435	-
Shareholder's Equity	-0.4%	1,199	1,203	1,455	1,464	1,482	1,473	1,484	1,494	1,500	1,280	1,171	1,182	1,193	1,178	1,190	1,201	1,216	-
Retained Earnings	-4.7%	-227	-217	-45.69	-37.12	-25.06	-34.93	-31.91	-26.42	-17.84	-7.80	-	-	-109	-	-	-	-55.76	-
Additional Paid-In Capital	0.9%	1,087	1,077	1,051	1,019	970	961	928	898	889	699	-	-	-	-	-	-	-	-
Shares Outstanding	-1.5%	113	115	-	108	101	100	98.00	97.00	92.00	88.00	-	-	128	-	-	-	127	-
Minority Interest	-0.7%	338	340	447	479	533	543	587	622	629	589	-	-	-	-	-	-	-	-
Float	-	-	-	526	-	-	-	811	-	-	-	866	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q2
Cashflow From Operations	-50.4%	4,709	9,487	12,037	14,957	-4,220	10,685	15,481	13,633	4,219	-948	8,414	13,527	8,673	-	-	-	-	-
Share Based Compensation	10.5%	13,254	11,994	12,363	11,128	11,424	9,133	9,005	6,872	5,619	2,317	1,615	406	417	-	-	-	-	-
Cashflow From Investing	200.6%	54,407	-54,059	1,340	-33,470	-67,886	-3,984	-10,181	-166,852	-41,069	-440	-1,380	-3,842	-15,866	-	-	-	-	-
Cashflow From Financing	41.5%	-6,062	-10,366	-5,631	-3,525	-9,457	-6,115	-6,748	-4,376	234,677	152,757	-1,766	-1,296	-2,861	-	-	-	-	-
Buy Backs	-	-	-	-	-	-	-	-	-	138,960	-63,209	-	-	-	-	-	-	-	-

DH Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Income Statement [Abstract]

Revenue

$ 251,415

$ 222,653

$ 166,154

Cost of revenue:

Cost of revenue exclusive of amortization

34,740

25,866

19,421

Amortization

12,742

16,759

21,268

Gross profit

203,933

180,028

125,465

Operating expenses:

Sales and marketing

94,534

89,585

56,387

Product development

42,441

34,890

18,565

General and administrative

58,861

51,561

32,864

Depreciation and amortization

39,008

40,145

38,679

Transaction, integration and restructuring expenses

11,489

7,890

6,287

Goodwill impairment

287,400

0

Total operating expenses

533,733

224,071

152,782

Loss from operations

(329,800)

(44,043)

(27,317)

Other income (expense), net:

Interest income

13,644

2,787

29

Interest expense

(15,203)

(11,200)

(25,900)

Other income, net

23,179

10,579

294

Loss on extinguishment of debt

0

(9,873)

Total other income (expense), net

21,620

2,166

(35,450)

Loss before income taxes

(308,180)

(41,877)

(62,767)

Benefit from income taxes

18,553

17,698

443

Net loss

(289,627)

(24,179)

(62,324)

Less: Net loss attributable to Definitive OpCo prior to the Reorganization Transactions

0

(34,068)

Less: Net loss attributable to noncontrolling interests

(87,239)

(16,957)

(10,416)

Net loss attributable to Definitive Healthcare Corp.

$ (202,388)

$ (7,222)

$ (17,840)

Net loss per share of Class A Common Stock:

Basic and diluted

$ (1.79)

$ (0.07)

$ (0.19)

Basic and diluted

$ (1.79)

$ (0.07)

$ (0.19)

Weighted average Common Stock outstanding:

Basic and diluted

^[1]

112,764,537

101,114,105

91,916,151

Basic and diluted

^[1]

112,764,537

101,114,105

91,916,151

[1]

Basic and diluted net loss per share of Class A Common Stock is applicable only for the years ended December 31, 2023 and 2022 and for the period from September 15, 2021 through December 31, 2021, which is the period following the IPO and related Reorganization Transactions. See Note 20 for the number of shares used in the computation of net loss per share of Class A Common Stock and the basis for the computation of net loss per share.

DH Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 130,976	$ 146,934
Short-term investments	177,092	184,939
Accounts receivable, net	59,249	58,799
Prepaid expenses and other assets	13,120	12,686
Deferred contract costs	13,490	10,387
Total current assets	393,927	413,745
Property and equipment, net	4,471	4,464
Operating lease right-of-use assets, net	9,594	9,681
Other assets	2,388	4,683
Deferred contract costs, net of current portion	17,320	14,596
Intangible assets, net	323,121	350,722
Goodwill	1,075,080	1,324,733
Total assets	1,825,901	2,122,624
Current liabilities:
Accounts payable	5,787	3,948
Accrued expenses and other liabilities	51,529	26,855
Deferred revenue	97,377	99,692
Term loan	13,750	8,594
Operating lease liabilities	2,239	1,521
Total current liabilities	170,682	140,610
Long term liabilities:
Deferred revenue	9	236
Term loan	242,567	255,765
Operating lease liabilities	9,372	9,969
Tax receivable agreements liability	127,000	155,111
Deferred tax liabilities	67,163	75,737
Other liabilities	9,934	3,251
Total liabilities	626,727	640,679
Commitments and Contingencies (Note 14)
Equity:
Additional paid-in capital	1,086,581	970,207
Accumulated other comprehensive income	2,109	3,668
Accumulated deficit	(227,450)	(25,062)
Noncontrolling interests	337,817	533,027
Total equity	1,199,174	1,481,945
Total liabilities and equity	1,825,901	2,122,624
Common Class A
Equity:
Common stock, value	117	105
Common Class B
Equity:
Common stock, value	$ 0	$ 0

About Definitive Healthcare Corp.

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution. The company's platform consists of various functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers; and other diversified companies comprising staffing firms and commercial real estate companies, financial institutions, and other organizations in the healthcare ecosystem. The company was founded in 2011 and is headquartered in Framingham, Massachusetts.

CEO	Mr. Robert W. Musslewhite J.D.
WEBSITE	definitivehc.com
INDUSTRY	Healthcare Plans
EMPLOYEES	946

Definitive Healthcare Corp. Frequently Asked Questions

What is the ticker symbol for Definitive Healthcare Corp.? What does DH stand for in stocks?

DH is the stock ticker symbol of Definitive Healthcare Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Definitive Healthcare Corp. (DH)?

As of Fri Apr 26 2024, market cap of Definitive Healthcare Corp. is 822.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DH stock?

You can check DH's fair value in chart for subscribers.

What is the fair value of DH stock?

You can check DH's fair value in chart for subscribers. The fair value of Definitive Healthcare Corp. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Definitive Healthcare Corp. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Definitive Healthcare Corp. a good stock to buy?

The fair value guage provides a quick view whether DH is over valued or under valued. Whether Definitive Healthcare Corp. is cheap or expensive depends on the assumptions which impact Definitive Healthcare Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DH.

What is Definitive Healthcare Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, DH's PE ratio (Price to Earnings) is -4 and Price to Sales (PS) ratio is 3.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DH PE ratio will change depending on the future growth rate expectations of investors.